This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

JNJ-17305600

Shire Pharmaceuticals Group PLC

Drug Names(s): GRI-1, GlyT-1

Description: GlyT-1 is a glycine transporter in the brain. Glycine reuptake inhibitors increase the level of glycine, a co-agonist at the glycine modulatory site (GMS) of the glutamate NMDA receptor.

Deal Structure: The program was originally developed by Allelix Biopharmaceuticals (merged with NPS in 1999) who partnered with Janssen Pharmaceutica.

NPS and Johnson and Johnson
In October 1998, NPS entered into a collaborative agreement with Janssen for the research, development and commercialization of new drugs for the treatment of schizophrenia and dementia. The research phase of this collaboration ended in October 2000. On August 4, 2008, Janssen notified NPS that they were terminating the agreement. To date, NPS received research support and milestone payments totaling $2.9 million under this agreement, which payments are non-refundable. In addition, as a result of this termination by Janssen, the rights to any compounds or products were transferred to NPS.

NPS and Shire
In January 2015, Shire and NPS Pharmaceuticals entered into a merger agreement pursuant to which Shire will acquire all the outstanding shares of NPS Pharma for $46.00 per share in cash,...See full deal structure in Biomedtracker


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug